Teriparatide

bone density conservation agents

Thuốc Gốc

Biotech

CAS: 52232-67-4

ATC: H05AA02

ĐG : Eli Lilly & Co. , http://www.lilly.com

CTHH: C₁₈₁H₂₉₁N₅₅O₅₁S₂

PTK: 4117.7150

Teriparatide (recombinant human parathyroid hormone) is a potent anabolic agent used in the treatment of osteoporosis. It is manufactured and marketed by Eli Lilly and Company.

Nhận Dạng Quốc Tế & Đặc Tính Hóa Học

Công thức hóa học

C₁₈₁H₂₉₁N₅₅O₅₁S₂

Phân tử khối

4117.7150

Dược Lực Học : Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density.

Cơ Chế Tác Dụng : Teriparatide (recombinant human parathyroid hormone) is a potent anabolic agent used in the treatment of osteoporosis. It is manufactured and marketed by Eli Lilly and Company. Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.

Dược Động Học :

▧ Absorption :
Bioavailability is 95% following subcutaneous injection.
▧ Volume of Distribution :
* 0.12 L/kg
▧ Metabolism :
Hepatic
▧ Route of Elimination :
Peripheral metabolism of PTH is believed to occur by non-specific enzymatic mechanisms in the liver followed by excretion via the kidneys. The 24-hour urine excretion of calcium was reduced by a clinically unimportant amount (15%).
▧ Clearance :
* 62 L/hr [Women] * 94 L/hr [Men]

Độc Tính : Effects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.

Chỉ Định : For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.

Liều Lượng & Cách Dùng : Solution - Subcutaneous

Dữ Kiện Thương Mại

Giá thị trường

Biệt dược thương mại : Forteo 750 mcg/3 ml pen

Giá bán buôn : USD >295.26

Đơn vị tính : ml

Nhà Sản Xuất

Công ty : Eli Lilly and Company

Sản phẩm biệt dược : Forsteo
Công ty : Eli Lilly and Company

Sản phẩm biệt dược : Forteo

Đóng gói

Công ty : Eli Lilly & Co.

Website : http://www.lilly.com
Công ty : Physicians Total Care Inc.

Website : http://www.physicianstotalcare.com

Tài Liệu Tham Khảo Thêm

drugbank

http://www.drugbank.ca/drugs/DB06285

KEGG Drug

http://www.genome.jp/dbget-bin/www_bget?drug:D06078

National Drug Code Directory

http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0002-8400-01

PharmGKB

http://www.pharmgkb.org/drug/PA451620

Wikipedia

http://en.wikipedia.org/wiki/Teriparatide

Drugs.com

http://www.drugs.com/cdi/teriparatide.html

Bạn thấy hài lòng ?

Bạn chưa hài lòng ?

... loading